438 related articles for article (PubMed ID: 23833016)
1. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
2. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
3. Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wu J; Huang H
Drug Des Devel Ther; 2020; 14():3977-3982. PubMed ID: 33061302
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
5. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
9. Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.
Nearchou A; Valachis A; Lind P; Akre O; Sandström P
Clin Genitourin Cancer; 2015 Aug; 13(4):280-286. PubMed ID: 25442773
[TBL] [Abstract][Full Text] [Related]
10. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
11. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
13. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
[TBL] [Abstract][Full Text] [Related]
18. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.
Srinivas S; Stein D; Teltsch DY; Tao S; Cisar L; Ramaswamy K
J Oncol Pharm Pract; 2018 Dec; 24(8):574-583. PubMed ID: 28732453
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
